Shirin David

Elevate Trust and Transparency with Vanta Trust Center

Retrieved on: 
수요일, 11월 8, 2023
Software, Technology, Security, Shirin David, Organization, Acquisition, Digital Trust Center, Multimedia, ROI, Trust, Salesforce, DocuSign, Collection, Automation, Online shopping

Vanta , the leading trust management platform, today announced the launch of Vanta Trust Center , a single destination for companies to showcase their security and compliance posture, build trust and streamline security reviews.

Key Points: 
  • Vanta , the leading trust management platform, today announced the launch of Vanta Trust Center , a single destination for companies to showcase their security and compliance posture, build trust and streamline security reviews.
  • View the full release here: https://www.businesswire.com/news/home/20231108321214/en/
    Vanta Trust Center is a single destination for companies to showcase their security and compliance posture, build trust and streamline security reviews.
  • When paired with Vanta AI’s Questionnaire Automation, Trust Center significantly reduces the manual, repetitive tasks hampering security and sales teams, freeing up valuable time and resources while enhancing customer trust.
  • “Vanta's Trust Center lets us communicate our real-time security status transparently, reducing the need for lengthy questionnaires and differentiating us in a competitive market.”
    For more information about the Vanta Trust Center, visit: www.vanta.com/products/trust-center .

Signeasy launches eSignature integration for HubSpot CRM

Retrieved on: 
수요일, 11월 8, 2023
Luigi, Shirin David, Google Drive, Microsoft, Google Workspace, SharePoint, Signature, Bed sheet, HubSpot, Salesforce, SMB, CRM, Marketplace, Satellite navigation device, Sales, Video game, DALLAS, Gmail

DALLAS, Nov. 8, 2023 /PRNewswire/ -- Signeasy, a leading eSignature and contract workflow platform, today announced that it is integrating with the HubSpot CRM. For sales professionals across the globe using HubSpot as their go-to CRM, Signeasy will offer an intuitive and secure way to send, track, and manage all kinds of contracts, NDAs, agreements, and other supporting documents.

Key Points: 
  • A powerful addition to its seamless integrations with Google Workspace, Office 365, Salesforce, and more
    DALLAS, Nov. 8, 2023 /PRNewswire/ -- Signeasy, a leading eSignature and contract workflow platform , today announced that it is integrating with the HubSpot CRM.
  • For sales professionals across the globe using HubSpot as their go-to CRM, Signeasy will offer an intuitive and secure way to send, track, and manage all kinds of contracts, NDAs, agreements, and other supporting documents.
  • Signeasy for HubSpot aims to simplify contracts and accelerate sales in SMB and mid-market companies.
  • This integration fuses HubSpot's CRM prowess with Signeasy's contract workflow capabilities, helping sales leaders scale operations and delight customers—one contract at a time."

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
월요일, 11월 6, 2023
Shift, Research, AD, Food, Medicare, FOCUS, Narcolepsy, Doctor of Philosophy, Fibromyalgia, Prescription, New Drug Application, Agitation, Shift work, Shirin David, Physician, SG, Acquisition, Smoking, Amgen, Webcast, Somnolence, NDA, Safety, Therapy, Patient, Food and Drug Administration, Central nervous system, Eli Lilly and Company, Reboxetine, SWD, ES, MD, Migraine, Growth, Binge eating disorder, Breakthrough therapy, Total, FDA, Government, SYMPHONY, CMC, CNS, R, DSM-IV codes, Horizon Therapeutics, BED, Dextromethorphan/bupropion, NMDA, Eating disorder, Beauty salon, Video game, Pharmaceutical industry, Bank, Dietary supplement, Solriamfetol, ADHD, Medicaid

“Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.

Key Points: 
  • “Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.
  • Auvelity® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023.
  • Third quarter 2023 U.S. Sunosi total prescriptions increased by 16% versus the third quarter of 2022, and sequentially by 5% versus the second quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2023 financial results as well as to provide a corporate update.

SkyWater Announces Availability of Cadence Open-Source PDK and Reference Design for SkyWater’s 130 nm Process

Retrieved on: 
금요일, 11월 3, 2023
Mobile, Wireless, Technology, Training, Defense, Government Technology, Other Defense, Contracts, University, IOT (Internet of Things), Education, Semiconductor, Security, Nanotechnology, Other Manufacturing, Other Technology, Engineering, Networks, Internet, Automotive Manufacturing, Hardware, Aerospace, Electronic Design Automation, Manufacturing, Consumer Electronics, Spectre, Cadence Design Systems, Inc. v. Avanti Corp, Shirin David, SkyWater Technology, Workforce, Kurdistan, Curriculum, PDK, Student, CMOS, NDA, GitHub, Silicon, VLSI, Video game, 3D printing, Nursing, Internet of things, Cadence

SkyWater Technology , (Nasdaq: SKYT), the trusted technology realization partner today announced a new SkyWater open-source 130 nm process design kit (PDK) from Cadence Design Systems, Inc., which will be available in the Cadence® VLSI (very large-scale integration) Fundamentals Education Kit.

Key Points: 
  • SkyWater Technology , (Nasdaq: SKYT), the trusted technology realization partner today announced a new SkyWater open-source 130 nm process design kit (PDK) from Cadence Design Systems, Inc., which will be available in the Cadence® VLSI (very large-scale integration) Fundamentals Education Kit.
  • To overcome this issue, SkyWater collaborated with Cadence to create an open-source chip manufacturing program on 130 nm CMOS process (SKY130).
  • The SKY130 process has gained popularity among academia and researchers and can be easily accessed from GitHub with no NDA necessary.
  • The design is based on a simple Arm-based microprocessor and is being migrated to the SKY130 PDK.

Announcing Digital Most Favored Nations Elections, a New Standard for Efficient and Transparent MFN Elections

Retrieved on: 
수요일, 11월 1, 2023
Intelligence, GP, Shirin David, Automation, Frustration, MFN, 2020 NRL Grand Final, LP record, Risk, Confusion, SAN, Insight, Uncertainty, GM, Financial adviser, Motive

SAN FRANCISCO, Nov. 1, 2023 /PRNewswire/ -- Ontra, the leader in contract automation and intelligence, today announced the launch of Digital Most Favored Nations ("dMFN") elections, a new purpose-built solution designed to help private fund managers accelerate the investor MFN election process. The dMFN feature is available within Ontra's Insight platform. It streamlines the MFN process, simplifying form creation and ongoing obligation compliance, while reducing fund expenses and the risk of election errors. 

Key Points: 
  • SAN FRANCISCO, Nov. 1, 2023 /PRNewswire/ -- Ontra, the leader in contract automation and intelligence, today announced the launch of Digital Most Favored Nations ("dMFN") elections, a new purpose-built solution designed to help private fund managers accelerate the investor MFN election process.
  • It streamlines the MFN process, simplifying form creation and ongoing obligation compliance, while reducing fund expenses and the risk of election errors.
  • "We're excited to use Insight to complete MFN elections quickly, reduce costs, and create a best-in-class investor experience.
  • For more information about how Insight's dMFN functionality is transforming the way private equity completes the MFN election process, visit www.ontra.ai/solutions/digital-mfn-election-process/

Lakewood-Amedex Announces Leadership Changes

Retrieved on: 
수요일, 11월 1, 2023
Medical Affairs Bureau, Pharmacology, Exact Sciences (company), Bayer, Radiology, Infection, Organic chemistry, Therapy, Shirin David, Drug discovery, Science, technology, engineering, and mathematics, Publication, Drug, Inflammation, Internal medicine, Development, Drug development, Senior, Free University of Berlin, Research and development, University, DRS, Free University, CV, Pharmacy, Agent handling, Cancer, Doctor of Philosophy, Pharmaceutical industry, Management, Nursing, Research, Science, Pfizer

UNIVERSITY PARK, Fla., Nov. 1, 2023 /PRNewswire/ -- Lakewood-Amedex Inc., a privately held, clinical-stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins™, today announced that Peter B. Corr, Ph.D., who has served as board chairman since 2020, was named Executive Chairman and will assume the strategic responsibilities of former CEO Steve Parkinson who left the company at the request of the Board. Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP. He retired from Pfizer Inc. in 2006 where he was Senior Vice President for Science and Technology, in addition to leading worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development. His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/

Key Points: 
  • Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP.
  • Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development.
  • His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/
    The Company also announced leadership promotions in the organization for Thomas Balzer, M.D., Ph.D., Senior Vice President for Clinical Development, and Kelvin Cooper, Ph.D., Vice President of Research and Development.
  • We look forward to their continued contributions as we work to advance our Research and Clinical Development programs."

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Retrieved on: 
화요일, 10월 24, 2023
Surgery, Medical Supplies, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, New Drug Application, Full, Shirin David, Vernal keratoconjunctivitis, Tobramycin, Acquisition, VKC, Keratitis, Allergic conjunctivitis, Risk, Marketing, Cornea, Conjunctivitis, Eye, AmerisourceBergen, NDA, McKesson Corporation, Pharmaceutical industry

NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.

Key Points: 
  • NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
  • ZERVIATE® (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for treating ocular itching associated with allergic conjunctivitis.
  • Harrow announced its acquisition of the U.S. commercial rights of these products in July of 2023.
  • To date, Harrow has been receiving profit transfers on these products; however, with the transfer of the NDAs completed, Harrow has launched these products in the U.S. under the Harrow name.

Wolters Kluwer to showcase legal solutions at the 2023 ACC Annual Meeting

Retrieved on: 
월요일, 10월 16, 2023
Annual general meeting, IP, Shirin David, Research, Corporation, Wolters Kluwer, Association of Corporate Counsel, Intellectual property, Software as a service, ACC, Risk, RE, Corporate lawyer, KPI-driven code analysis, Associate, Insurance

NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Wolters Kluwer Legal and Regulatory U.S. will present a product showcase session during the 2023 Association of Corporate Counsel (ACC) Annual Meeting in San Antonio, Texas. The session entitled "Contracts and Entities and Ticketing, Oh My!" will take place at 11:45 AM CST on October 23. Members from Wolters Kluwer's Legisway and VitalLaw® for Corporate Counsel will also be at booth #122 during the conference to provide product demos and meet with clients.

Key Points: 
  • NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Wolters Kluwer Legal and Regulatory U.S. will present a product showcase session during the 2023 Association of Corporate Counsel (ACC) Annual Meeting in San Antonio, Texas.
  • Members from Wolters Kluwer's Legisway and VitalLaw® for Corporate Counsel will also be at booth #122 during the conference to provide product demos and meet with clients.
  • VitalLaw® is Wolters Kluwer's intuitive research platform that provides corporate counsel and legal professionals with comprehensive support and world-class analysis in key practice areas.
  • The 2023 ACC Annual Meeting is the world's largest gathering of in-house counsel and offers three days of solution-based education, a world-class exhibit hall showcasing the latest legal technology, and ample networking opportunities.

AITX Provides Roll-Up Regarding Its Key Markets, End-Users, and Use Cases

Retrieved on: 
수요일, 10월 4, 2023
The Security Institute, Theft, TravelCenters of America, Crime, RAD, Professional, Food, Data collection, Foodservice, Ingram Micro, Reinharz, Hospital, 7-Eleven, House, CPP, GXO, SCOT, West Side, AVA, Artificial intelligence, Sustainable Energy Utility, Shirin David, Assault, Environment, Education, PSP, Safety, Renewable energy, Risk management, Medical device

“We are so proud of our incredible customer base and the dealers that brought many of them to RAD,” said Steve Reinharz, CEO of AITX and RAD.

Key Points: 
  • “We are so proud of our incredible customer base and the dealers that brought many of them to RAD,” said Steve Reinharz, CEO of AITX and RAD.
  • Our team works tirelessly to make sure that every client is treated with the respect and professionalism they deserve.
  • In the automotive world and the controlled environments of financial institutions, RAD has successfully reduced common security challenges like trespassing and theft.
  • Regardless of the market or use case, RAD seamlessly blends its technological innovation with real-world applications, establishing a reliable security presence.

Founding Partners of Sculptor Capital Comment on Special Committee’s Rejection of Offer to Purchase the Company for $12.76 per Share

Retrieved on: 
목요일, 8월 31, 2023
Other Professional Services, Asset Management, Professional Services, Finance, Committee, Disclosure, Shirin David, SCU, United States Congressional Joint Special Committee on Conditions of Indian Tribes, RITM, NYSE, Auction

The Founding Partners of Sculptor Capital Management, Inc. (“Sculptor” or the “Company”) (NYSE: SCU), which include Daniel S. Och, Harold Kelly, Richard Lyon, James O’Connor and Zoltan Varga, today commented on the recent disclosure that the Sculptor Special Committee of the Board of Directors has rejected a $12.76 per share offer by a consortium of well-known investors (identified as Bidder J in Sculptor disclosures).

Key Points: 
  • The Founding Partners of Sculptor Capital Management, Inc. (“Sculptor” or the “Company”) (NYSE: SCU), which include Daniel S. Och, Harold Kelly, Richard Lyon, James O’Connor and Zoltan Varga, today commented on the recent disclosure that the Sculptor Special Committee of the Board of Directors has rejected a $12.76 per share offer by a consortium of well-known investors (identified as Bidder J in Sculptor disclosures).
  • The Special Committee has disclosed its continued support for an $11.15 per share offer from Rithm Capital Corp (“Rithm”) (NYSE: RITM)).
  • It seems evident that such a group could augment Sculptor’s investment team while paying much more cash to the shareholders.
  • The shareholders and investors who must consent to the Rithm bid are entitled to full disclosure about the available alternatives.”
    View source version on businesswire.com: https://www.businesswire.com/news/home/20230831707533/en/